Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caring Agency Seeks Stable Partner For FOB User Fee Negotiations

Executive Summary

FDA's negotiations with the generics industry on ANDA user fees are just getting off the ground, but the agency is already gearing up for the next user fee frontier: biosimilars.
Advertisement

Related Content

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected
Hospira The Holdout
Hospira The Holdout
Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"
Generic User Fee Negotiations: Should Different Kinds Of ANDAs Pay More?

Topics

Advertisement
UsernamePublicRestriction

Register

PS052643

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel